Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035932 · ClinicalTrials.gov registry record · Phase 3
Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
A Phase 3 study of HIV Infections, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 571
- Enrollment target
- 20
- Study locations
NCT00035932: Completed Phase 3 study of HIV Infections, sponsored by Bristol-Myers Squibb.
NCT00035932 is a Phase 3 study of HIV Infections that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 571 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035932, a Phase 3 study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 571 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn how well atazanavir (ATV) works in combination with ritonavir (RTV) or saquinavir (SQV) with tenofovir (TDF) and a nucleoside to reduce the viral load of treatment experienced subjects with human immunodeficiency virus (HIV). There is a comparison arm with lopinavir (LPV)/RTV and TDF and a nucleoside.
Conditions Studied
Interventions
- DRUG Atazanavir + ritonavir + tenofovir + nucleoside
- DRUG Atazanavir + saquinavir + tenofovir + nucleoside
- DRUG Lopinavir/ritonavir + tenofovir + nucleoside
Study Locations (20)
Florida
- - Altamonte Springs
- - Fort Lauderdale
- - Fort Lauderdale
- - Miami Beach
- - Orlando
California
- - San Francisco
- - Torrance
Massachusetts
- - Brookline
- - Fall River
New Jersey
- - East Orange
- - Newark
New York
- - Buffalo
- - Manhasset
Colorado
- - Boulder
Georgia
- - Decatur
Hawaii
- - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2001-11 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
What the finished NCT00035932 record still lists
NCT00035932 is an interventional study that assigns participants to a tested intervention. The registered 571 participants enrollment target is mid-sized for trials with a published cap, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (28% higher).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Atazanavir + ritonavir + tenofovir + nucleoside is the first listed.
NCT00035932 names 20 study sites across 12 states, led by Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00035932 about?
NCT00035932 is a clinical study titled "Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV". The purpose of this study is to learn how well atazanavir (ATV) works in combination with ritonavir (RTV) or saquinavir (SQV) with tenofovir (TDF) and a nucleoside to reduce the viral load of treatment experienced subjects with human immunodeficiency virus (HIV). There is a comparison arm with lopin...
What is the current status of trial NCT00035932?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 571 participants. The study started on 2001-11. Estimated completion is 2009-03.
What conditions does trial NCT00035932 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00035932?
The interventions under investigation include: Atazanavir + ritonavir + tenofovir + nucleoside (DRUG), Atazanavir + saquinavir + tenofovir + nucleoside (DRUG), Lopinavir/ritonavir + tenofovir + nucleoside (DRUG).
Who is sponsoring clinical trial NCT00035932?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00035932 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00035932's enrollment target sits among peer trials
571 55th of 542 higher than 488 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04410796 · 571 participants · Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- NCT05131022 · 572 participants · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06615050 · 572 participants · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia